1. Home
  2. CADL vs CIGL Comparison

CADL vs CIGL Comparison

Compare CADL & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Candel Therapeutics Inc.

CADL

Candel Therapeutics Inc.

HOLD

Current Price

$6.20

Market Cap

357.4M

Sector

Health Care

ML Signal

HOLD

CIGL

Concorde International Group Ltd Class A Ordinary Shares

HOLD

Current Price

$1.99

Market Cap

417.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CADL
CIGL
Founded
1999
1997
Country
United States
Singapore
Employees
N/A
134
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
357.4M
417.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CADL
CIGL
Price
$6.20
$1.99
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$19.00
N/A
AVG Volume (30 Days)
1.7M
41.6K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
58.62
N/A
EPS
N/A
N/A
Revenue
$125,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.34
$1.40
52 Week High
$7.66
$25.00

Technical Indicators

Market Signals
Indicator
CADL
CIGL
Relative Strength Index (RSI) 56.36 56.54
Support Level $5.42 $1.55
Resistance Level $6.41 $2.28
Average True Range (ATR) 0.48 0.16
MACD 0.09 0.01
Stochastic Oscillator 49.22 69.49

Price Performance

Historical Comparison
CADL
CIGL

About CADL Candel Therapeutics Inc.

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

About CIGL Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.

Share on Social Networks: